U.S. Psychedelic Mushroom Market (2025 - 2030) Size, Share & Trends Analysis Report By Product (Psilocybe, Gymnopilus, Panaeolus), By Form (Fresh/Whole, Dried, Processed), By Application, And Segment Forecasts

U.S. Psychedelic Mushroom Market Trends

The U.S. psychedelic mushroom market size was estimated at USD 2.25 billion in 2024 and is expected to grow at a CAGR of 11.5% from 2025 to 2030. There is a growing movement in the U.S. to decriminalize the use of psychedelic mushrooms, as well as other plant-based entheogens. Several cities and states have already taken steps to decriminalize or legalize the use of these substances, which has led to increased interest and demand.

Psychedelic mushrooms have shown promise in treating a range of mental health conditions, including depression, anxiety, PTSD, and addiction. As more research is conducted on their therapeutic potential, demand for these substances is likely to increase.

The main applications of psychedelic mushrooms is in the treatment of depression and anxiety disorders. Psilocybin can help alleviate symptoms of depression and anxiety, and can even produce long-lasting positive changes in personality and behavior. This has led to a growing interest in the use of psilocybin as a potential treatment for a range of mental health conditions, including post-traumatic stress disorder (PTSD), addiction, and end-of-life anxiety in patients with terminal illness.

The driving force behind the U.S. psychedelic mushroom market is the growing movement to decriminalize these substances. Some cities, such as Denver, Colorado and Oakland, California, have passed laws that make enforcement of laws against the possession and use of psychedelic mushrooms a low priority. In addition, there are advocacy groups working to change state and federal drug laws to allow for greater access to psychedelic therapies.

There is also a growing body of scientific research into the potential therapeutic benefits of psychedelic mushrooms and other psychedelics. Several clinical trials have been conducted or are currently underway to investigate the safety and efficacy of these substances in treating various mental health conditions. If these studies yield promising results, it could lead to increased mainstream acceptance of psychedelic therapies and greater demand for psychedelic mushrooms.

Research has shown that psilocybin can produce changes in brain activity that may help alleviate symptoms of depression. In clinical trials, participants with depression who were given psilocybin reported significant improvements in their mood, as well as reduced anxiety and feelings of hopelessness.

Compass Pathways, a mental healthcare company, has conducted a trial indicating that psilocybin, the psychedelic substance present in magic mushrooms, can be effective in alleviating severe depression when administered in combination with psychotherapy.

Product Insights

The Psilocybe segment accounted for a revenue share of 90.0% in 2024. The demand for psilocybe psychedelic mushrooms in the U.S. is growing for a variety of reasons, including changing attitudes towards psychedelic drugs, increasing research into their therapeutic potential, and a growing trend towards natural and holistic health practices.

The shift in attitudes towards psychedelic drugs in recent years, particularly in the context of mental health treatment. Researchers have found that certain psychedelic substances, including psilocybin, may be effective in treating conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD). This has led to increased interest and advocacy for the use of these substances in therapeutic settings.

The Gymnopilus segment is expected to grow at a CAGR of 11.6% from 2025 to 2030. The increasing interest in Gymnopilus mushrooms, a type of psychedelic mushroom, can be attributed to growing awareness of their potential therapeutic benefits. These mushrooms contain psilocybin, which has been studied for its effects on mental health, particularly in treating depression, anxiety, and PTSD. As research into psychedelics expands and cultural acceptance grows, more people are exploring Gymnopilus for both recreational and medicinal purposes, contributing to its rising popularity.

Form Insights

The market for dried psychedelic mushroom accounted for a revenue share of 56.7% in 2024. The dried psychedelic mushrooms are popular in the U.S. because they are seen as a natural and relatively safe way to experience altered states of consciousness. Additionally, there has been growing interest in the potential therapeutic benefits of psilocybin, which may be driving some of the demand for these mushrooms. It's also worth noting that the internet has made it easier to purchase a wide range of products, including dried psychedelic mushrooms, which may contribute to their popularity in the U.S.

The market for processed psychedelic mushrooms is expected to grow at a CAGR of 12.2% from 2025 to 2030. People may prefer processed psychedelic mushrooms like gums and gellies because they are easier to consume than dried mushrooms and may have a more consistent dose of psilocybin. These products may also be more discreet and convenient to use, as they can be consumed without the need for any additional equipment or preparation.

In addition, various product launches by key players in the U.S. phychedelic mushroom industry is increasing the demand for this segment. For instance, in January 2023, Galaxy treats launched Amanita mushroom gummies. These psychedelic gummies, which come in two flavors (Watermelon and Mango) and each contain 350mg of amanita mushroom extract, are especially designed to produce a relaxed, psychedelic high.

Application Insights

The recreational segment dominated the U.S. phychedelic mushroom industry accounted for a revenue share of 28.3% in 2024. Some people use psychedelic mushrooms recreationally to experience altered states of consciousness and to induce euphoria and creativity. Psychedelic mushrooms contain psilocybin, which is a powerful hallucinogenic compound that can produce a range of effects on the mind and body. 

When ingested, psilocybin is metabolized into psilocin, which binds to serotonin receptors in the brain. This leads to changes in perception, thought, and emotion, including altered sensory perception, mood changes, and states of consciousness.

In addition, users report experiencing a sense of euphoria or "mystical" experience, while others may have a more challenging experience, including anxiety, paranoia, or feelings of confusion. Creativity and enhanced problem-solving abilities are also commonly reported effects of psilocybin use.

De-addiction application mushroom is expected to grow at a CAGR of 12.3% from 2025 to 2030. Psychedelic mushrooms, have been studied as a potential treatment for depression.

Psilocybin,  found in psychedelic mushrooms, is a potential treatment for substance abuse when paired with therapy. It has shown promise for treating addiction to alcohol, drugs, and nicotine, but its long-term effectiveness and high cost in healthcare settings are still uncertain. While not addictive, psilocybin has downsides including anxiety and side effects like vomiting or loss of coordination. Some are concerned that it is not being evaluated in low-income communities where addiction is prevalent.

Key U.S. Psychedelic Mushroom Company Insights

The U.S. psychedelic mushroom industry is expected to witness moderate competition among the companies owing to the presence of numerous players across the industry. Owing to changing consumer trends, numerous companies are expanding their product portfolio to gain a competitive edge in the market. Some of the key players include Shroomland, Galaxy Treats, Blissmushrooms, oneupmushroomsbar.com, Psychedelic Mushy, Psilocybin Lounge among others.

Manufacturers are increasingly engaged in R&D activities related to products that are used in the manufacturing of U.S. psychedelic mushrooms. They are also expanding their product portfolio to meet the growing demand for U.S. Psychedelic mushrooms from the application industry.

• In September 2023, Wiz Khalifa, a Grammy-winning rapper, launched a new brand called MISTERCAP'S, which is focused on promoting healthy living through culinary mushrooms, specifically non-psychedelic varieties. In partnership with Red Light Holland, which specializes in exotic mushrooms, MISTERCAP'S aims to educate consumers about the benefits of mushrooms while providing products such as at-home grow kits for Oyster, Shiitake, and Lion's Mane mushrooms.

U.S. Psychedelic Mushroom Market Report Scope

U.S. Psychedelic Mushroom Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global U.S. Psychedelic Mushroom market report based on product, form, and application:

• U.S. Psychedelic Mushroom Product type Outlook (Revenue, USD Million, 2018 - 2030)

  • Psilocybe

    • Psilocybe cubensis

    • Psilocybe semilanceata

    • Psilocybe azurescens

    • Psilocybe cyanescens

    • Psilocybe baeocystis

    • Others

  • Gymnopilus

    • Spectabilis

    • Others

  • Panaeolus

• U.S. Psychedelic Mushroom Form Outlook (Revenue, USD Million, 2018 - 2030)

  • Fresh/Whole

  • Dried

  • Processed

• U.S. Psychedelic Mushroom Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Depression Relief

  • Anxiety Relief

  • De-addiction

  • Recreational

  • Others